Neurocognitive Decline
6
2
2
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
33%
2 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
A Multifocal tDCS-EEG Protocol for Improving Symptoms of Mild Cognitive Impairment and Early Dementia
MISTIC Study: Atherosclerosis, Neurocognition & Cardiovascular Signaling
Comparison Between Analog Neurocognitive Tests Conducted by a Trained Test Leader Versus Self-administered Digital Tests
CONSTELLATIONS Living Lab: Improving the Care Transitions of Older Adults Living with Neurocognitive Disorders
Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning
Continuous Cellsaver and Neurocognitive Decline Post Cardiac Surgery